Table 1.
Baseline characteristics in VDAART and COPSAC2010.
| VDAART | COPSAC2010 | |||||||
|---|---|---|---|---|---|---|---|---|
| Mother rs12936231 genotype | P value | Mother rs12936231 genotype | P value | |||||
| GG | GC | CC | GG | GC | CC | |||
| N | 132 | 299 | 182 | 152 | 263 | 148 | ||
| Vitamin D3 intervention, N (%) | 60 (46%) | 158 (53%) | 84 (46%) | 0.223 | 71 (47%) | 136 (52%) | 77 (52%) | 0.559 |
| Maternal race, N (%) | 0.009 | N.A. | ||||||
| African American | 67 (51%) | 115 (39%) | 80 (44%) | 0 | 0 | 0 | ||
| Caucasian | 55 (42%) | 131 (44%) | 65 (36%) | 152 (100%) | 263 (100%) | 148 (100%) | ||
| Other | 10 (8%) | 53 (18%) | 37 (20%) | 0 | 0 | 0 | ||
| Maternal asthma, N (%) | 49 (37%) | 114 (38%) | 85 (47%) | 0.121 | 39 (26%) | 59 (22%) | 51 (35%) | 0.025 |
| Maternal baseline* serum 25-hyroxyvitamin D level (ng/ml, mean (SD)) | 23.0 (9.6) | 23.7 (10.8) | 22.5 (10.6) | 0.457 | 30.7 (10.5) | 29.7 (9.3) | 31.7 (10.7) | 0.167 |
| Child rs12936231 genotype, N (%) | <0.001 | <0.001 | ||||||
| GG | 68 (51%) | 55 (21%) | 0 | 70 (51%) | 62 (26%) | 0 | ||
| GC | 64 (49%) | 137 (52%) | 82 (49%) | 68 (49%) | 116 (49%) | 67 (52%) | ||
| CC | 0 | 74 (28%) | 85 (51%) | 0 | 57 (24%) | 62 (48%) | ||
| Child sex (male, N (%)) | 63 (48%) | 160 (54%) | 101 (55%) | 0.377 | 74 (49%) | 135 (51%) | 78 (53%) | 0.775 |
| Child asthma/recurrent wheezing at 0–3 years, N (%) | 34 (26%) | 93 (31%) | 50 (28%) | 0.467 | 25 (16%) | 45 (17%) | 30 (20%) | 0.640 |
*
Before intervention, i.e. at 10–18 gestational weeks for VDAART and at 22–26 gestational weeks for COPSAC2010.